Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Asset Writedowns and Impairment (2024)

Historic Asset Writedowns and Impairment for Regenxbio (RGNX) over the last 1 years, with Q1 2024 value amounting to $2.1 million.

  • Regenxbio's Asset Writedowns and Impairment changed N/A to $2.1 million in Q1 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is N/A changed from last year.
  • Per Regenxbio's latest filing, its Asset Writedowns and Impairment stood at $2.1 million for Q1 2024.
  • In the past 5 years, Regenxbio's Asset Writedowns and Impairment ranged from a high of $2.1 million in Q1 2024 and a low of $2.1 million during Q1 2024